Virus therapy shows promise in Hard-to-Treat colorectal cancer trial
NCT ID NCT07446322
First seen Mar 13, 2026 · Last updated May 16, 2026 · Updated 5 times
Summary
This study tests whether adding a virus-based drug called pelareorep to standard chemotherapy can help people with a specific type of advanced colorectal cancer that has stopped responding to initial treatment. About 60 adults whose cancer has spread and has certain genetic features (RAS mutation, MSS) will be randomly assigned to receive either the standard chemo combo or the standard chemo plus pelareorep. The main goal is to see if the combination shrinks tumors more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCRC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Central Alabama Research
RECRUITINGHomewood, Alabama, 35209, United States
-
Summit Health Cancer Center
RECRUITINGFlorham Park, New Jersey, 07932, United States
Conditions
Explore the condition pages connected to this study.